^
Association details:
Biomarker:BRCA1 mutation
Cancer:Hormone Receptor Positive Breast Cancer
Drug Class:PARP inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Title:

Chemo- and Targeted Therapy for Patients With HER2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative

Published date:
07/29/2021
Excerpt:
Patients with HR-positive MBC with germline BRCA mutations no longer benefiting from endocrine therapy may be offered a poly (ADP-ribose) polymerase inhibitor rather than chemotherapy.
DOI:
10.1200/JCO.21.01374